Highway To FIM – How To Avoid
Roadblocks During Preclinical

Thursday, November 23rd, 14:30-17:00 (Food & Networking start at 17:00)
Berlin BioCube, Campus Berlin-Buch, Robert-Rössle-Straße 10, 13125 Berlin (room E.32 in the building D95)


Early drug discovery represents a critical phase in the pharmaceutical industry, where the identification and development of novel therapeutic agents commence. Discovering tomorrow's medicine requires the interplay of many disciplines, from screening to medicinal chemistry, biophysics, in vitro and in vivo pharmacology, DMPK as well as toxicology. In this event, our NUVISAN experts will share their experiences in early drug discovery research, highlighting the key principles, challenges, and innovative approaches that drive this vital phase of drug development.


14:30 - 15:00
Registration & Coffee

15:00 -15:10
Welcome Reception & Introduction

Dr. Stephanie Urschel (VP Business Development)
Dr. Alexander Aslanidis (Business Development Manager)

15:10 - 15:50
Redefining drug discovery: where hightech meets digital

Dr. Ulrike Scheib (Business Development Manager)
Dr. Dusan Petrovic (Head of Digital Life Sciences)

15:50 – 16:20
Brake the driver: a journey into KRAS inhibition via SOS1, fragment screening, and HTS

Dr. Benjamin Bader (Head of Screening)

16:20 - 17:00
Targeting the Hippo pathway in cancer: Phenotyping screening, target deconvolution, and lead optimization of novel small molecule inhibitors

Dr. Martin Lange (Head of Translational Research)

Networking & Food


Stephanie Urschel

Dr. Stephanie Urschel

VP Business Development

Visit LinkedIn Profile

Dr. Alexander Aslanidis

Business Development Manager

Visit LinkedIn Profile

Dr. Ulrike Scheib

Business Development Manager

Visit LinkedIn Profile

Dr. Dusan Petrovic

Head of Digital Life Sciences

Visit LinkedIn Profile

Dr. Benjamin Bader

Head of Screening

Visit LinkedIn Profile

Martin Lange

Dr. Martin Lange

Head of Translational Research

Visit LinkedIn Profile